|15.19|| -0.20 / -1.30%|
Mesoblast Ltd. engages in the development of bio-therapeutics based on its proprietary cell-based and protein technologies. Its proprietary cell-based core technologies include highly purified, immunoselected Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Its protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1). The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
|Silviu Itescu||Chief Executive Officer, Executive Director & MD|
|Paul Hodgkinson||Chief Financial Officer|
|Donna L. Skerrett||Chief Medical Officer|
|Suzanne Lipe||Vice President-Operations|
|Susan Elizabeth MacLeman||Head-Commercialization|